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We investigated the usefulness of Holter monitoring to detect cardiac disease and predict 
future cardiovascular risk in asymptomatic diabetics. This is a multi-center, prospective 
study in 406 asymptomatic diabetics. They were categorized into three groups based on 
findings of Holter monitoring. Three-hundred and seventy-seven met inclusion criteria 
and were classified as low (n=172), moderate (n=136) and high risk (n=69). Eighty-six 
in moderate and 53 in high risk receive further evaluation. Twenty-nine in moderate and 
25 in high risk were diagnosed as cardiac disease and 12 required additional treatment, 
including coronary intervention. Over 1.8 years of mean follow-up, 11 (16.5 per 1,000 
person-years) experienced cardiovascular events. The cumulative incidence in moderate 
and high risk was higher than that in low risk (p=0.029 and p = 0.014, respectively). Our 
study suggests that Holter monitoring may be a useful screening tool to detect cardiac 
disease and predict future cardiovascular risk in asymptomatic diabetics.  
 






     Coronary artery disease (CAD) is a leading cause of morbidity and mortality in 
diabetic patients.1 Diabetic patients without previous myocardial infarction have as a high 
risk of cardiovascular death and myocardial infarction as non-diabetic patients with 
previous myocardial infarction.2, 3 Considering the specific features of diabetic CAD, a 
concern is that myocardial ischemia can be silent with its first presentation of an acute 
coronary syndrome or a sudden death. The silent myocardial ischemia (SMI) is two to six 
times more common in the diabetic patients than in the non-diabetic patients.4 To identify 
CAD in diabetic patients without clear symptoms of CAD, risk factor based approach to 
the initial diagnostic evaluation and subsequent follow-up is recommended.5, 6 However, 
a recent study suggested that the conventional cardiac risk factors did not help to identify 
patients whose likelihood of having SMI was high.7 
     Holter monitoring is a non-invasive tool for assessing the frequency and duration 
of silent transient myocardial ischemia, by providing for the detection and analysis of 
arrhythmias and ST-segment deviation.8 While a variety of diagnostic tests for CAD 
require referrals to cardiologists, Holter monitoring is available to adopt in primary care 
for the assessment of patients with suspected cardiac diseases by general physicians. 
Current evidence suggests that Holter monitoring can improve assessment of future CAD 
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risk, particularly in patients who are post-acute myocardial infarction, those with acute 
coronary syndrome, and in patients in the acute post-operative period.9 There is, however, 
no current evidence that Holter monitoring in diabetic patients without history of cardiac 
disease improves future cardiac risk assessment or leads to better utilization of treatments.  
The Non-Invasive Holter monitoring Observation of New cardiac events in 
diabetics (NIHON) study was aimed at evaluating the usefulness of a Holter monitoring 
based screening strategy for asymptomatic diabetic patients. Here, we report the results 
of our study. 
Materials and Methods 
The NIHON study was a prospective, multi-center study. Four hundred and six 
patients with type 2 diabetes mellitus (DM) or impaired glucose tolerance (IGT) were 
enrolled at 28 clinics in Japan between July 2008 and July 2009.  
The study recruited asymptomatic patients aged over 20 years with Type 2 DM or 
IGT defined according to the 1999 Japan Diabetes Society criteria who had no history of 
organic heart disease but who did have one or more of the following risk factors: 
hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 
mmHg; early morning home blood pressure ≥130 mmHg systolic or ≥80 mmHg diastolic; 
or use of antihypertensive medications), dyslipidemia (LDL-cholesterol ≥140 mg/dl; 
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HDL-cholesterol <40 mg/dl; triglyceride ≥150 mg/dl; or medication with lipid-lowering 
agents), proteinuria, diabetic nephropathy (microalbuminuria or estimated glomerular 
filtration rate [eGFR] ≤60 ml/min), abdominal obesity (waist circumference ≥85cm in 
men, ≥90cm in women), diabetic retinopathy, diabetic neuropathy, history of 
cerebrovascular disease, internal carotid artery stenosis (intima-media complex ≥1.2mm), 
or peripheral artery disease ([PAD] ankle brachial pressure index ≤0.8).  
This study was approved by the Institutional Review Boards of Kitano Hospital, 
the Tazuke Kofukai Medical Research Institute, and the Institutional Review Boards at 
the individual collaborating physicians’ institutions, which also approved the protocol 
when requested. After obtaining written informed consent, baseline data were recorded 
including 24-h Holter monitoring.  
Holter monitoring 
Electrocardiograms were recorded continuously on digital storage, Holtrec (Nihon 
Kohden Corporation, Tokyo, Japan) with the use of two electrodes (leads CM5 and 
NASA). All Holter recordings were sent to a central site by using Net De Holter (Morioh 
Co. Ltd, Morioka, Japan) via the internet. An expert cardiologist blinded to the patient’s 
baseline characteristics interpreted all recordings and categorized them into the three 
following groups: low risk, moderate risk and high risk. These reports were overviewed 
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by expert cardiologists in Department of EBM Research, Institute for advancement of 
clinical and translational, Kyoto University Hospital.  
The low risk group included patients without abnormalities or with only mild 
abnormalities which did not meet the following criteria of the moderate and high risk. 
The moderate risk group included patients with second-degree atrioventricular block; sick 
sinus syndrome, sinoatrial block, sinus arrest, sinus bradycardia, or total heart beat [THB] 
≤80,000/24h; paroxysmal atrial flutter, paroxysmal atrial fibrillation, sinus tachycardia 
(THB ≥120,000/24h), premature atrial contractions (≥5% of THB); premature ventricular 
complexes (PVCs) (≥5% of THB) or multifocal PVCs (Lown grades 2 to 3); and the 
possibility of ischemic ST-T changes. Ischemic ST-T changes were defined as: 1) ST 
segment depression at least 1 mm below the baseline ST position measured at 80 ms after 
the J point, 2) lasting for at least one minute and no more than 20 minutes, and 3) separated 
from other episodes by ≥1min. The possibility of ischemic ST-T changes was defined by 
the presence of 1) without 2) or 3). The high risk group included patients with third-
degree atrioventricular block; sinus arrest ≥5 min; paroxysmal atrial flutter or atrial 
fibrillation lasting more than 30 min, persistent atrial flutter or atrial fibrillation; frequent 
PVCs such as couplets or triplets, ventricular tachycardia, ventricular fibrillation, R on T 
extrasystoles (Lown grades 4a and above); and heart rate-related ischemic ST-T changes 
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with or without long lasting ST-depression, T wave inversion, or symptoms. Ischemic ST-
T changes were defined as ST segment depression at least 1 mm below the baseline ST 
position measured at 80 ms after the J point, lasting for at least one minute and no more 
than 20 minutes, and separated from other episodes by ≥1min. The definition of 
stratification was determined preliminarily by reference to Minnesota code and the 
guideline by the Japan Society of Ningen Dock. 
Other risk stratification 
We also stratified patients based on the following criteria: (1) American Diabetes 
Association (ADA) criteria: The ADA recommended screening for myocardial ischemia 
in diabetic patients with one of the following: PAD; carotid artery disease; at least two of 
five cardiovascular risk factors including dyslipidemia, hypertension, current smoking, 
family history of premature CAD, or albuminuria.10 (2) The French-speaking Societies 
for diabetes & cardiology (ALFEDIAM/SFC) criteria: The ALFEDIAM/SFC 
recommended screening for myocardial ischemia in diabetic patients with one of the 
following: age over 60 years; diabetic duration over 10 years and at least two other 
cardiovascular risk factors; PAD; carotid artery disease; proteinuria.6 
Evaluation and follow-up 
Attending physicians received a report of their patients’ results of Holter recordings 
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including group categorizations (low, moderate, and high risk), and communicated the 
results to the patients. Patients with moderate or high risk were referred to cardiologists 
for further evaluations and follow-up. Evaluation and management decisions were made 
according to the best-effort judgments of the cardiologists.  
Cardiovascular events 
The cardiovascular end point was a composite of myocardial infarction, stroke, 
coronary revascularization, hospitalization for heart failure, hospitalization for 
arrhythmias, hospitalization for angina pectoris or SMI, hospitalization for aneurysm, 
hospitalization for PAD, or dialysis.  
Statistical analysis 
We summarized the baseline characteristics separately for groups (low, moderate, 
and high risk), using means and standard deviation for normally distributed data, medians 
and interquartile range for non-normally distributed data, and percentages for categorical 
data. We used the Kaplan-Meier method with a log-rank test to compare the incidence of 
cardiovascular events between groups. To calculate cardiac event rates, we divided the 
number of cardiac events by person-years of follow-up, defined as the period from the 
date of first visit to the date of the first event or 31 January 2011, whichever came first. 
We performed univariate Cox proportional hazard regression analyses to evaluate the 
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relationships between risk classification by Holter and cardiovascular events. Statistical 
analyses were performed using STATA version 12.1 (STATA, Texas, USA). 
Results 
Characteristics 
Of the 406 patients enrolled at the baseline screening, we analyzed a total of 377 
patients, 360 for type 2 DM, and 17 for IGT. We classified them as low risk (n = 172), 
moderate risk (n=136), and high risk (n=69) based on the results of Holter recordings 
(Figure 1). Table 1 showed the baseline characteristics of these patients. Low risk patients 
were younger, higher HbA1c, and had a higher prevalence of diabetic complications 
(nephropathy and retinopathy) than high risk patients. There are no trend between High 
risk by ADA or ALFEDIAM/SFC criteria and the groups by Holter monitoring (p=0.927, 
p=0.392). 
Table 2 showed the detailed results of Holter recordings in patients with moderate 
and high risk. Both groups had high prevalence of ventricular arrhythmias (PVCs, 86.0% 
in moderate risk; NSVT or VT, 91.3% in high risk patients). In addition, 16 (11.8%) 
patients in moderate risk and 11 (15.9%) patients in high risk had silent ischemic ST 
changes on Holter recordings.  
Additional testing and medical treatment 
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Eighty-six (63.2%) patients in moderate risk and 53 (76.8%) in high risk were 
referred to a cardiology department during follow-up (Figure 2). Non-invasive tests were 
performed in 51 patients at moderate risk and in 42 at high risk (Supplementary table 1), 
and 29 in moderate risk and 25 in high risk were diagnosed as cardiac disease (Table 2). 
In the diagnosed cardiac diseases, structural heart disease had a higher prevalence 
compared to ischemic heart disease in both moderate and high risk. 12 patients (5 in 
moderate risk and 7 in high risk) required additional treatment, including a percutaneous 
coronary intervention (PCI; 1 in moderate risk and 2 in high risk). 
Cardiovascular Outcomes 
Over 1.8 years of mean follow-up, accounting for 665 person-years, 11 patients 
experienced cardiovascular events (only in patients with type 2 DM): 1 at low risk (the 
incidence rate 3.3 per 1,000 person-years), 6 at moderate risk (24.9 per 1,000 person-
years), and 4 at high risk (32.4 per 1,000 person-years). We observed only heart disease 
including ischemic heart disease, structural heart disease, and arrhythmias (Table 3). The 
cumulative incidence was significantly higher in patients at high risk than in those at low 
risk (p = 0.014; Figure 3), and higher in patients at moderate risk than those at low risk 
(p = 0.029). Patients with high risk showed a trend toward increased cardiovascular events 
(p for trend = 0.028). After exclusion of IGT patients, this trend was significant in patients 
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with type 2 DM (p for trend = 0.034). Table 4 showed clinical factors associated with 
cardiovascular events. We also found that age, HbA1c, and diabetic neuropathy were 
associated with increased risk of cardiovascular events. The current two criteria (ADA 
and ALFEDIAM/SFC) commonly used CAD screening in patients with diabetes were not 
predictors of significant cardiovascular events in our setting. The low number of 
cardiovascular events precluded multivariate analyses.  
Discussion 
In the present study, Holter monitoring detected high prevalence of abnormality 
including ischemic ST changes in asymptomatic diabetic patients. Patients classified as 
moderate or high risk by Holter monitoring were diagnosed as cardiac disease with high 
frequency and some required additional treatments including PCI. The proportions of 
patients who leaded to the diagnosis of cardiac disease and received additional treatment 
were higher in the high risk group than in the moderate risk group. Further, diabetic 
patients at high risk detected by Holter monitoring had a poorer prognosis than those with 
low risk.  
     The current strategy of screening patients with diabetes for advanced asymptomatic 
CAD is a risk factor-guided approach to identify patients with high cardiac risk whose 
outcomes might be improved through more aggressive intervention 10. Both ADA and 
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ALFEDIAM/SFC considered that multiple risk factors in the same patient substantially 
increase the overall cardiovascular risk 12 and that intervention directed at risk factors 
significantly improved cardiovascular prognosis.13 In addition, considering the high 
likelihood of a positive screening test result, ALFFEDIAM/SFC defined the first selection 
criterion for inclusion in a screening program for SMI as age > 60 years and a duration of 
diabetes of > 10 years.6 However, those traditional risk factors do not always predict 
which patients will have abnormal screening test,7, 14 and negative screening tests in 
diabetic patients do not uniformly confer a benign prognosis.15, 16 In the Detection of 
Ischemia in Asymptomatic Diabetics (DIAD) study,17 none of the current stratification 
schemes using conventional cardiac risk factors predicted abnormalities on screening-
stress myocardial perfusion imaging (MPI); and neither the presence nor severity of MPI 
abnormalities was greater in the higher-risk patients. Our present study confirms these 
findings in an Asian diabetic population whose mean BMI at baseline was around 25 
kg/m2. Together, these findings suggest that current recommendations for routine 
cardiovascular screening in asymptomatic patients with diabetes require reconsideration. 
    The very limited number of clinical trials conducted to date means that no 
comprehensive strategy for CAD screening in diabetic patients can be proposed.10, 11 
Although exercise treadmill test is recommended in asymptomatic diabetic patients or in 
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individuals who are about to embark on moderate to high-intensity exercise,18, 19 its use 
is limited to patients who can exercise and have a normal baseline electrocardiogram. 
Furthermore, many diabetic patients are obese and have additional comorbidities such as 
hypertension, peripheral neuropathy, PAD, decreased functional capacity, and physical 
deconditioning — all of which may adversely influence the ability of the patient to 
exercise for a sufficiently long time to allow the evaluation of ischemic changes on 
electrocardiography.20, 21 While the clinical usefulness of several cardiac imaging for 
CAD detection has continued to improve over the past few years, their use is hampered 
by the disadvantages of radiation exposure22 and costs, and are not appropriate as an initial 
screening test. The Detection of Ischemia in Asymptomatic Diabetes (DIAD) study 
reported that among 1,123 diabetic patients without symptomatic or previously 
recognized CAD, many of whom had 2 or more cardiac risk factors, MPI screening for 
myocardial ischemia did not significantly reduce cardiac event rates over 4.8 years.23 
Although the coronary artery calcium score by cardiac computed tomography is a 
valuable marker for the overall coronary atherosclerotic burden and identifies 
asymptomatic individuals at higher risk for inducible ischemia,24, 25 the usefulness of 
screening asymptomatic moderate risk populations is currently unknown.26 
Holter monitoring is non-invasive, inexpensive, widely available, and one of the 
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most frequently used modalities in the assessment of suspected or proven cardiovascular 
disease. The prevalence of SMI in diabetes as assessed by Holter monitoring varies 
between 35% and 58%.27-30 Although the predicted value of cardiac disease by Holter 
monitoring in diabetic patients is expected to be more useful than that by other non-
invasive modalities, findings to date have been inconsistent.  
In Asymptomatic Cardiac Ischemia Pilot (ACIP) study, diabetic patients tended to 
have less measurable ischemia during the 48-hour Holter monitoring despite their having 
more extensive and diffuse CAD.32 One reason for these results is that evaluation was 
restricted to Holter monitoring of ST segment changes. Holter monitoring provides for 
the detection and analysis of two important factors, arrhythmias and ST-segment 
deviation.8 In the NIHON study, we assessed both the arrhythmias and ST-segment 
changes, and ventricular arrhythmias detected by Holter monitoring led to the diagnosis 
of SMI in patients who needed for additional cardiac evaluations and treatments.  
There are several limitations to the present study and analysis. First, as not all 
patients in high and moderate risk had referred to cardiology, there is a possible risk of 
selection bias. Second, another important limitation is that an oral glucose tolerance test 
was not performed to diagnose IGT or newly-diagnosed DM. Third, cardiovascular event 
rates were low due to the relatively short duration of follow-up, and the study does not 
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have sufficient statistical power to allow for the adjustment of potential confounding 
factors. In our study, low-risk group had a higher HbA1c level and a higher prevalence of 
diabetic complications compared to moderate or high risk group at baseline. We need to 
further evaluation the associations between Holter monitoring and cardiovascular 
outcomes with a variety of risk factors including a glycemic control. Forth, we did not 
evaluate the possibility of cardiac disease among low risk patients. One low-risk patient 
experienced a cardiovascular event during 1.8 years of mean follow-up, but this event 
rate (3.3 per 1,000 person-years) was the lowest among groups. Finally, we were unable 
to compare the Holter screening and non-screening groups because the present study was 
not designed to assess the hypothesis. In the NIHON study, we suggested that the potential 
benefits of screening by Holter monitoring would be greater for diabetic patients with at 
least one risk factor. Studies are needed to directly evaluate whether screening for CAD 
by Holter monitoring identifies diabetic patients at high cardiac risk and whether it affects 
clinical outcome compared with no screening. 
In conclusion, Holter monitoring detected high prevalence of abnormality including 
ischemic ST changes and arrhythmias, and enabled to detect cardiac disease and stratify 
the risk of serious cardiovascular events in asymptomatic diabetic patients. These findings 
suggest that a screening by a combination of conventional risk factors and Holter 
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monitoring may be advantageous to early detection of CAD and the prevention of 
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Figure 1. Study flow chart. 
 
Figure 2. Cardiac diagnosis and additional treatments in patients with moderate or 
high risk. 
Tx = treatment; PCI = percutaneous coronary intervention; IHD = ischemic heart 
disease. 
 
Figure 3. Cardiovascular events from Kaplan-Meier estimates.  
  
 
